Additional Proxy Soliciting Materials (definitive) (defa14a)
19 Abril 2023 - 9:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment
No. )
Filed by the Registrant x |
|
Filed by a Party other than the Registrant
o |
|
Check the appropriate box: |
o |
Preliminary Proxy Statement |
o |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
o |
Definitive Proxy Statement |
x |
Definitive Additional Materials |
o |
Soliciting Material under §240.14a-12 |
COMMUNITY
HEALTHCARE TRUST INCORPORATED |
(Name of Registrant as Specified In Its Charter)
|
Not Applicable |
(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)
|
Payment of Filing Fee (Check
the appropriate box): |
x |
No fee required. |
o |
Fee paid previously with preliminary materials. |
o |
Fee computed on table in exhibit required by Item 25(b) per
Exchange Act Rules 14a6(i)(1) and 0-11. |
On April 19, 2023, Community Healthcare Trust Incorporated (the
“Company”) made available to stockholders the following communication in connection with its 2023 Annual Meeting of Stockholders
to be held on May 4, 2023. The Company filed a proxy statement with the Securities and Exchange Commission on March 16, 2023 describing
the matters to be voted on at the 2023 Annual Meeting. This communication should be read in conjunction with the proxy statement.
Dear Stockholder:
This letter addresses an advisory report issued by the proxy advisory
firm Institutional Shareholder Services (“ISS”) on April 14, 2023, regarding the Company’s 2023 Annual Meeting
of Stockholders scheduled for May 4, 2023. In its report, ISS recommends that our stockholders vote against the non-binding
advisory vote on executive compensation (also known as “say-on-pay”). We respectfully disagree with ISS’s recommendation
for the reasons outlined below and recommend you vote FOR the non-binding advisory vote on executive compensation.
Since our IPO, all named executive officers (“NEOs”) have
taken 100% of all their compensation – salary, bonus and long-term incentive – in restricted common stock with 8-year
cliff vesting and significant risk of forfeiture. We believe our stockholders like our management and employees taking their
compensation in the form of restricted common stock with long-term vesting and significant risk of forfeiture. Other than annual raises,
our NEO compensation system is the same it has been since the Company’s inception.
Although ISS cites Chief Executive Officer (“CEO”) pay
being 2x that of median ISS peers as justification for pay-for-performance misalignment, their analysis doesn’t take into account
the strong alignment created by taking 100% of that compensation in stock with 8-year cliff vesting. Further, ISS did not incorporate
the newly required Pay for Performance Table in their analysis which clearly shows how share performance impacts overall compensation.
As disclosed in the table, the CEO’s adjusted compensation for
2022 was $1,654,573. See below:
| |
2022 | | |
2021 | | |
2020 | |
Summary Compensation Table Total | |
$ | 4,540,328 | | |
$ | 4,788,861 | | |
$ | 3,737,563 | |
Deduction for Amounts Reported under the "Stock Awards" Column in the SCT | |
| (2,820,373 | ) | |
| (3,164,711 | ) | |
| (2,530,931 | ) |
Increase for Fair Value of Awards Granted during year that Remain Unvested as of Year End | |
| 2,450,331 | | |
| 3,055,580 | | |
| 2,504,933 | |
Increase (Deduction) for Change in Fair Value from Prior Year End to Current Year End of Awards Granted in Prior Years that were Outstanding and Unvested as of Year End | |
| (3,471,338 | ) | |
| 38,081 | | |
| 785,536 | |
Increase based on Dividends or Other Earnings Paid during the year prior to Vesting Date of Award | |
| 955,625 | | |
| 754,706 | | |
| 585,103 | |
Total Adjustments | |
| (2,885,755 | ) | |
| 683,656 | | |
| 1,344,641 | |
Compensation Actually Paid | |
$ | 1,654,573 | | |
$ | 5,472,517 | | |
$ | 5,082,204 | |
It should be noted that with Timothy Wallace’s passing, and
separation of the Chairman and CEO roles, the new CEO’s salary is now $647,250 which is closer to ISS peers.
We remain proud of the many best practices we have incorporated into our compensation programs over the years
to reward performance and align executives’ interests with our stockholders. We believe stock compensation with substantial risk
of forfeiture is the best way to align pay with long term performance.
We urge you to vote FOR Proposal
2 - the non-binding advisory vote on executive compensation.
Commmunity Healthcare (NYSE:CHCT)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Commmunity Healthcare (NYSE:CHCT)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024